Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11546557 | 0.77 | POLB (0.43) | TSHRMAPK1ALDH1A1KDM4EPKM | |
| SCHEMBL27928568 | 0.77 | TSHR (0.38) | TSHR | |
| SCHEMBL146433 | 0.74 | PDE2A (0.37) | TSHRMAPK1NOS3NOS2ALDH1A1 | |
| SCHEMBL149760 | 0.74 | TSHR (0.37) | TSHRMAPK1NOS3NOS2ALDH1A1 | |
| SCHEMBL9725680 | 0.73 | TSHR (0.35) | TSHRMAPK1NOS3NOS2ALDH1A1 | |
| SCHEMBL95846 | 0.73 | KIF11 (0.36) | TSHRMAPK1NOS3NOS2ALDH1A1 | |
| SCHEMBL3081819 | 0.73 | MGLL (0.41) | TSHRMAPK1NOS3NOS2KDM4E | |
| SCHEMBL146946 | 0.73 | TSHR (0.35) | TSHRMAPK1NOS3NOS2ALDH1A1 | |
| SCHEMBL148163 | 0.73 | TSHR (0.35) | TSHRMAPK1NOS3NOS2ALDH1A1 | |
| SCHEMBL101521 | 0.73 | PDE2A (0.36) | TSHRMAPK1NOS3NOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | claimed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | claimed |
| CN-115819366-B | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-111511719-B | Novel quinoline compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116217475-A | Preparation method of polysubstituted quinoline derivative | 中国医学科学院阜外医院深圳医院(深圳市孙逸仙心血管医院) | 2023-06-06 | — | — | CN | disclosed |
| CN-115819366-A | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-114502538-A | Substituted 3, 4-dihydroquinazolines for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114144401-A | Novel quinazoline compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111511719-A | Quinoline compounds for the treatment and prophylaxis of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-109369671-A | As Raf kinases and/or the fused tricyclic carbamide compounds of Raf kinases dimer inhibitor | 百济神州有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-105452223-B | Fused Tricyclic Ureas as Raf Kinase and/or Raf Kinase Dimer Inhibitors | 百济神州有限公司 | 2018-10-02 | — | — | CN | disclosed |
| EP-1008601-A2 | Method for producing palladium complex compound | Central Glass Company, Limited (JP) | 2000-06-14 | — | — | EP | disclosed |
| US-6043242-A | TREATING A MAMMAL AFFLICTED WITH A DISEASE BASED ON HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0946559-A2 | IMIDAZOPYRIDAZINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028299-A2 | IMIDAZOPYRIDAZINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
| EP-0379145-A2 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| US-4263441-A | BENZOXAZOLE DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-04-21 | — | — | US | disclosed |
| US-4219352-A | Herbicidal 4-trifluoromethyl-4-nitrodiphenyl ethers | ROHM AND HAAS COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
| US-RE30361-E | Herbicidal 4-trifluoromethyl-4-nitrodiphenyl ethers | ROHM AND HAAS COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| US-4076741-A | Herbicidal 4-trifluoromethyl-4-nitrodiphenyl ethers | ROHM AND HAAS COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | TSHR 898/4885MAPK1 3096/4885NOS3 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.